#blood cancer

Chemotherapy drugs are increasingly in short supply, warn the American Cancer Society and ACS CAN about this life-threatening situation.

The Leukemia & Lymphoma Society highlights resources for blood cancer patients, survivors, families and caregivers.

Experts stress the need for targeted efforts to increase vaccine uptake among cancer patients with lower vaccination rates.

Cancer Health editor Trent Straube introduces the spring 2023 issue, including articles on treatments, exercise, clinical trials and more.

Fred Hutch study suggests certain immune cells are the source of antibodies that attack donated organs.

Scientists from the Leukemia & Lymphoma Society participated in a career development program for college members. Here’s what they said.

A team of experts on acute promyelocytic leukemia (APL) were available by phone or email to other oncologists treating this rare cancer.

Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.

Immunotherapy drug Blincyto extends life for those with acute lymphoblastic leukemia (ALL) in remission

The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.

Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.

Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.

UPDATE: On October 25, the FDA approved Tecvayli (teclistamab) to treat some people with multiple myeloma.

Safety tips for the evolving pandemic. Plus: Which groups—such as those with cancer or HIV—are at higher risk for COVID-19 complications?

People with blood cancers or prostate cancer might be particularly vulnerable to COVID-19 complications.